Share Price and Basic Stock Data
Last Updated: December 11, 2025, 9:02 pm
| PEG Ratio | -13.93 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Lotus Eye Hospital & Institute Ltd operates in the Hospitals & Medical Services sector, focusing primarily on providing eye care. As of the latest reporting period, the company’s share price stood at ₹105 with a market capitalization of ₹219 Cr. Over the past year, Lotus Eye has demonstrated a steady increase in sales, reporting ₹47.03 Cr in FY 2023, which rose to ₹48.20 Cr in FY 2024. The trailing twelve months (TTM) revenue reached ₹50.19 Cr. However, the quarterly sales figures have shown some variability, with a notable dip to ₹10.88 Cr in March 2024, before rebounding to ₹13.52 Cr by June 2025. This fluctuation suggests that while the company is capable of generating substantial revenue, it may face challenges in maintaining consistent sales growth, a characteristic that could concern investors looking for stability.
Profitability and Efficiency Metrics
Profitability remains a critical area of concern for Lotus Eye, highlighted by a P/E ratio of 326 and a return on equity (ROE) of just 1.22%. The company’s operating profit margin (OPM) has also faced pressure, recorded at 10.95% recently, down from a high of 19.55% in June 2022. The net profit for the latest period was ₹0.65 Cr, a decline from previous highs of ₹1.96 Cr in FY 2023. This decline in profitability, alongside rising operational expenses, indicates that the company may be struggling to convert sales into profit effectively. The interest coverage ratio (ICR) of 13.34x suggests that while the company can comfortably cover its interest obligations, the overall profitability metrics raise questions about its operational efficiency and cost management strategies.
Balance Sheet Strength and Financial Ratios
Lotus Eye’s balance sheet presents a mixed picture. On one hand, it boasts reserves of ₹39.82 Cr and relatively low borrowings of ₹4.80 Cr, indicating a strong equity position. This is further supported by a current ratio of 1.56, which is above the industry norm, suggesting that the company is well-positioned to meet its short-term liabilities. However, the return on capital employed (ROCE) at 2.99% reflects underutilization of capital, which might hinder growth prospects. The price-to-book value ratio stands at 2.42x, suggesting that the stock is valued significantly above its book value, potentially limiting upside for new investors. Overall, while the balance sheet is solid, the efficiency and returns generated from the capital employed require improvement to attract more discerning investors.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Lotus Eye reveals a significant presence of public shareholders, accounting for 59.33% of total ownership. Promoters hold a declining stake of 40.63%, down from over 58% in late 2022. The absence of foreign institutional investors (FIIs) and minimal domestic institutional investment (DIIs) at 0.02% could indicate a lack of confidence among larger institutional players. This shift in promoter shareholding may raise red flags for potential investors, as a decrease could signal concerns about the company’s future direction or governance. The number of shareholders has fluctuated, with a recent count of 10,777, which could suggest an increase in retail interest, albeit without substantial institutional backing.
Outlook, Risks, and Final Insight
Looking ahead, Lotus Eye Hospital & Institute Ltd faces a challenging landscape. The fluctuating sales and profitability metrics suggest that while the company has the potential to grow, it must navigate operational inefficiencies and competitive pressures effectively. Risks include the possibility of continued volatility in revenue, which could deter new investments, along with the heavy reliance on a shrinking promoter stake. Additionally, without significant institutional investment, the stock may lack the credibility needed to attract larger capital inflows. Investors should weigh these factors carefully, considering whether the company’s operational improvements can translate into sustainable growth. Ultimately, while the fundamentals show promise, the road ahead requires careful navigation of both internal and external challenges to realize its full potential.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Lotus Eye Hospital & Institute Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Dr Lalchandani Labs Ltd | 7.80 Cr. | 18.0 | 28.7/9.80 | 16.6 | 23.4 | 0.00 % | 2.81 % | 3.08 % | 10.0 |
| Asarfi Hospital Ltd | 384 Cr. | 195 | 221/72.9 | 27.3 | 45.2 | 0.00 % | 15.8 % | 14.1 % | 10.0 |
| Narayana Hrudayalaya Ltd | 38,520 Cr. | 1,885 | 2,372/1,257 | 45.3 | 199 | 0.24 % | 20.8 % | 24.2 % | 10.0 |
| Lotus Eye Hospital & Institute Ltd | 246 Cr. | 118 | 141/55.0 | 367 | 29.2 | 0.00 % | 2.99 % | 1.22 % | 10.0 |
| Industry Average | 13,050.00 Cr | 554.00 | 114.05 | 74.20 | 0.06% | 10.60% | 10.65% | 10.00 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 11.87 | 11.86 | 12.14 | 11.17 | 12.57 | 12.73 | 12.03 | 10.88 | 12.89 | 12.91 | 12.25 | 11.51 | 13.52 |
| Expenses | 9.55 | 10.10 | 10.03 | 9.78 | 10.18 | 10.92 | 10.45 | 10.12 | 11.23 | 11.76 | 11.46 | 11.68 | 12.04 |
| Operating Profit | 2.32 | 1.76 | 2.11 | 1.39 | 2.39 | 1.81 | 1.58 | 0.76 | 1.66 | 1.15 | 0.79 | -0.17 | 1.48 |
| OPM % | 19.55% | 14.84% | 17.38% | 12.44% | 19.01% | 14.22% | 13.13% | 6.99% | 12.88% | 8.91% | 6.45% | -1.48% | 10.95% |
| Other Income | 0.24 | 0.23 | 0.32 | 0.36 | 0.29 | 0.28 | 0.34 | 0.40 | 0.31 | 0.27 | 0.22 | 0.52 | 0.19 |
| Interest | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.01 | 0.04 | 0.03 | 0.06 | 0.08 | 0.13 | 0.09 | 0.12 |
| Depreciation | 0.68 | 0.75 | 0.77 | 0.78 | 0.73 | 0.89 | 0.98 | 1.12 | 1.06 | 1.23 | 1.31 | -0.58 | 0.82 |
| Profit before tax | 1.85 | 1.21 | 1.64 | 0.95 | 1.93 | 1.19 | 0.90 | 0.01 | 0.85 | 0.11 | -0.43 | 0.84 | 0.73 |
| Tax % | 26.49% | 24.79% | 29.88% | 31.58% | 27.98% | 28.57% | 26.67% | -200.00% | 28.24% | 9.09% | -44.19% | 70.24% | 24.66% |
| Net Profit | 1.37 | 0.90 | 1.16 | 0.65 | 1.38 | 0.85 | 0.66 | 0.02 | 0.62 | 0.10 | -0.24 | 0.25 | 0.54 |
| EPS in Rs | 0.66 | 0.43 | 0.56 | 0.31 | 0.66 | 0.41 | 0.32 | 0.01 | 0.30 | 0.05 | -0.12 | 0.12 | 0.26 |
Last Updated: August 20, 2025, 7:40 am
Below is a detailed analysis of the quarterly data for Lotus Eye Hospital & Institute Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 13.52 Cr.. The value appears strong and on an upward trend. It has increased from 11.51 Cr. (Mar 2025) to 13.52 Cr., marking an increase of 2.01 Cr..
- For Expenses, as of Jun 2025, the value is 12.04 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11.68 Cr. (Mar 2025) to 12.04 Cr., marking an increase of 0.36 Cr..
- For Operating Profit, as of Jun 2025, the value is 1.48 Cr.. The value appears strong and on an upward trend. It has increased from -0.17 Cr. (Mar 2025) to 1.48 Cr., marking an increase of 1.65 Cr..
- For OPM %, as of Jun 2025, the value is 10.95%. The value appears strong and on an upward trend. It has increased from -1.48% (Mar 2025) to 10.95%, marking an increase of 12.43%.
- For Other Income, as of Jun 2025, the value is 0.19 Cr.. The value appears to be declining and may need further review. It has decreased from 0.52 Cr. (Mar 2025) to 0.19 Cr., marking a decrease of 0.33 Cr..
- For Interest, as of Jun 2025, the value is 0.12 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.09 Cr. (Mar 2025) to 0.12 Cr., marking an increase of 0.03 Cr..
- For Depreciation, as of Jun 2025, the value is 0.82 Cr.. The value appears to be increasing, which may not be favorable. It has increased from -0.58 Cr. (Mar 2025) to 0.82 Cr., marking an increase of 1.40 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.73 Cr.. The value appears to be declining and may need further review. It has decreased from 0.84 Cr. (Mar 2025) to 0.73 Cr., marking a decrease of 0.11 Cr..
- For Tax %, as of Jun 2025, the value is 24.66%. The value appears to be improving (decreasing) as expected. It has decreased from 70.24% (Mar 2025) to 24.66%, marking a decrease of 45.58%.
- For Net Profit, as of Jun 2025, the value is 0.54 Cr.. The value appears strong and on an upward trend. It has increased from 0.25 Cr. (Mar 2025) to 0.54 Cr., marking an increase of 0.29 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.26. The value appears strong and on an upward trend. It has increased from 0.12 (Mar 2025) to 0.26, marking an increase of 0.14.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:56 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 28.69 | 29.90 | 31.13 | 33.96 | 38.02 | 38.43 | 40.55 | 32.35 | 38.90 | 47.03 | 48.20 | 49.55 | 50.19 |
| Expenses | 25.40 | 27.72 | 27.14 | 30.63 | 33.68 | 35.21 | 36.57 | 28.73 | 32.98 | 39.35 | 41.57 | 45.99 | 46.94 |
| Operating Profit | 3.29 | 2.18 | 3.99 | 3.33 | 4.34 | 3.22 | 3.98 | 3.62 | 5.92 | 7.68 | 6.63 | 3.56 | 3.25 |
| OPM % | 11.47% | 7.29% | 12.82% | 9.81% | 11.42% | 8.38% | 9.82% | 11.19% | 15.22% | 16.33% | 13.76% | 7.18% | 6.48% |
| Other Income | 0.39 | 0.46 | 0.58 | 0.68 | 0.91 | 0.68 | 0.21 | 0.84 | 0.88 | 1.15 | 1.31 | 1.31 | 1.20 |
| Interest | 0.04 | 0.10 | 0.16 | 0.15 | 0.18 | 0.21 | 0.24 | 0.14 | 0.21 | 0.20 | 0.20 | 0.48 | 0.42 |
| Depreciation | 3.54 | 4.76 | 4.44 | 3.44 | 3.37 | 3.06 | 2.50 | 2.33 | 2.50 | 2.98 | 3.73 | 3.01 | 2.78 |
| Profit before tax | 0.10 | -2.22 | -0.03 | 0.42 | 1.70 | 0.63 | 1.45 | 1.99 | 4.09 | 5.65 | 4.01 | 1.38 | 1.25 |
| Tax % | 60.00% | -10.81% | -400.00% | -7.14% | -2.35% | -12.70% | 26.90% | 21.11% | 27.14% | 27.79% | 27.43% | 46.38% | |
| Net Profit | 0.04 | -1.98 | 0.10 | 0.44 | 1.75 | 0.71 | 1.06 | 1.57 | 2.98 | 4.08 | 2.91 | 0.74 | 0.65 |
| EPS in Rs | 0.02 | -0.95 | 0.05 | 0.21 | 0.84 | 0.34 | 0.51 | 0.75 | 1.43 | 1.96 | 1.40 | 0.36 | 0.31 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 236.36% | 59.43% | 0.00% | 0.00% | 66.24% | 34.90% | 25.49% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -5050.00% | 105.05% | 340.00% | 297.73% | -59.43% | 49.30% | 48.11% | 89.81% | 36.91% | -28.68% | -74.57% |
| Change in YoY Net Profit Growth (%) | 0.00% | 5155.05% | 234.95% | -42.27% | -357.16% | 108.72% | -1.18% | 41.70% | -52.90% | -65.59% | -45.89% |
Lotus Eye Hospital & Institute Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 4% |
| 3 Years: | 8% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -13% |
| 3 Years: | -38% |
| TTM: | -70% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 26% |
| 5 Years: | 33% |
| 3 Years: | 25% |
| 1 Year: | 61% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 4% |
| 3 Years: | 4% |
| Last Year: | 1% |
Last Updated: September 5, 2025, 9:50 am
Balance Sheet
Last Updated: December 4, 2025, 1:34 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 |
| Reserves | 30.57 | 28.59 | 28.69 | 29.26 | 29.84 | 29.32 | 30.46 | 31.90 | 33.81 | 36.78 | 38.61 | 39.20 | 39.82 |
| Borrowings | 0.18 | 0.83 | 0.66 | 0.48 | 0.29 | 0.22 | 0.32 | 0.40 | 1.24 | 0.67 | 1.11 | 3.43 | 4.80 |
| Other Liabilities | 7.01 | 6.20 | 4.68 | 4.40 | 7.28 | 6.18 | 6.53 | 6.12 | 5.75 | 4.93 | 6.11 | 6.14 | 6.09 |
| Total Liabilities | 58.56 | 56.42 | 54.83 | 54.94 | 58.21 | 56.52 | 58.11 | 59.22 | 61.60 | 63.18 | 66.63 | 69.57 | 71.51 |
| Fixed Assets | 46.94 | 47.04 | 43.57 | 41.32 | 42.52 | 44.14 | 42.67 | 40.54 | 44.07 | 44.18 | 48.65 | 54.07 | 55.17 |
| CWIP | 0.36 | 0.27 | 0.42 | 0.65 | 0.29 | 0.29 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.06 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 11.26 | 9.11 | 10.84 | 12.97 | 15.40 | 12.09 | 15.44 | 18.68 | 17.53 | 19.00 | 17.90 | 15.50 | 16.28 |
| Total Assets | 58.56 | 56.42 | 54.83 | 54.94 | 58.21 | 56.52 | 58.11 | 59.22 | 61.60 | 63.18 | 66.63 | 69.57 | 71.51 |
Below is a detailed analysis of the balance sheet data for Lotus Eye Hospital & Institute Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 20.80 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 20.80 Cr..
- For Reserves, as of Sep 2025, the value is 39.82 Cr.. The value appears strong and on an upward trend. It has increased from 39.20 Cr. (Mar 2025) to 39.82 Cr., marking an increase of 0.62 Cr..
- For Borrowings, as of Sep 2025, the value is 4.80 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 3.43 Cr. (Mar 2025) to 4.80 Cr., marking an increase of 1.37 Cr..
- For Other Liabilities, as of Sep 2025, the value is 6.09 Cr.. The value appears to be improving (decreasing). It has decreased from 6.14 Cr. (Mar 2025) to 6.09 Cr., marking a decrease of 0.05 Cr..
- For Total Liabilities, as of Sep 2025, the value is 71.51 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 69.57 Cr. (Mar 2025) to 71.51 Cr., marking an increase of 1.94 Cr..
- For Fixed Assets, as of Sep 2025, the value is 55.17 Cr.. The value appears strong and on an upward trend. It has increased from 54.07 Cr. (Mar 2025) to 55.17 Cr., marking an increase of 1.10 Cr..
- For CWIP, as of Sep 2025, the value is 0.06 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 0.06 Cr., marking an increase of 0.06 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 16.28 Cr.. The value appears strong and on an upward trend. It has increased from 15.50 Cr. (Mar 2025) to 16.28 Cr., marking an increase of 0.78 Cr..
- For Total Assets, as of Sep 2025, the value is 71.51 Cr.. The value appears strong and on an upward trend. It has increased from 69.57 Cr. (Mar 2025) to 71.51 Cr., marking an increase of 1.94 Cr..
Notably, the Reserves (39.82 Cr.) exceed the Borrowings (4.80 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 3.11 | 1.35 | 3.33 | 2.85 | 4.05 | 3.00 | 3.66 | 3.22 | 4.68 | 7.01 | 5.52 | 0.13 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 4.96 | 4.27 | 5.98 | 7.31 | 10.94 | 7.22 | 5.94 | 8.35 | 5.82 | 9.08 | 9.54 | 9.72 |
| Inventory Days | 166.70 | 121.54 | 113.25 | 60.22 | 79.23 | 128.20 | 124.42 | 138.82 | 150.03 | 153.60 | 170.30 | 193.62 |
| Days Payable | 130.52 | 125.08 | 105.51 | 87.32 | 129.95 | 167.37 | 170.41 | 220.72 | 231.21 | 173.42 | 183.56 | 169.86 |
| Cash Conversion Cycle | 41.14 | 0.73 | 13.72 | -19.79 | -39.78 | -31.95 | -40.05 | -73.54 | -75.37 | -10.74 | -3.72 | 33.48 |
| Working Capital Days | -13.10 | -19.90 | -8.56 | -8.92 | -26.02 | -15.39 | -21.33 | -23.92 | -16.33 | 8.61 | 4.85 | 0.00 |
| ROCE % | 0.27% | -4.23% | 0.24% | 1.19% | 3.63% | 1.66% | 4.67% | 3.92% | 7.91% | 10.25% | 7.07% | 2.99% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.36 | 1.40 | 1.96 | 1.44 | 0.75 |
| Diluted EPS (Rs.) | 0.36 | 1.40 | 1.96 | 1.44 | 0.75 |
| Cash EPS (Rs.) | 1.80 | 3.19 | 3.39 | 2.64 | 1.87 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 28.85 | 28.57 | 27.69 | 26.26 | 25.34 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 28.85 | 28.57 | 27.69 | 26.26 | 25.34 |
| Dividend / Share (Rs.) | 0.00 | 0.50 | 0.50 | 0.50 | 0.50 |
| Revenue From Operations / Share (Rs.) | 23.83 | 23.18 | 22.62 | 18.71 | 15.56 |
| PBDIT / Share (Rs.) | 2.28 | 3.77 | 4.20 | 3.24 | 2.07 |
| PBIT / Share (Rs.) | 0.83 | 1.97 | 2.77 | 2.03 | 0.95 |
| PBT / Share (Rs.) | 0.66 | 1.93 | 2.72 | 1.97 | 0.95 |
| Net Profit / Share (Rs.) | 0.35 | 1.40 | 1.96 | 1.44 | 0.75 |
| PBDIT Margin (%) | 9.55 | 16.24 | 18.56 | 17.30 | 13.30 |
| PBIT Margin (%) | 3.48 | 8.51 | 12.22 | 10.87 | 6.10 |
| PBT Margin (%) | 2.78 | 8.32 | 12.01 | 10.52 | 6.15 |
| Net Profit Margin (%) | 1.49 | 6.04 | 8.66 | 7.67 | 4.84 |
| Return on Networth / Equity (%) | 1.23 | 4.90 | 7.08 | 5.46 | 2.97 |
| Return on Capital Employeed (%) | 2.78 | 6.79 | 9.91 | 7.57 | 3.69 |
| Return On Assets (%) | 1.06 | 4.37 | 6.45 | 4.84 | 2.64 |
| Asset Turnover Ratio (%) | 0.72 | 0.74 | 0.75 | 0.64 | 0.55 |
| Current Ratio (X) | 1.56 | 2.25 | 2.83 | 2.24 | 2.34 |
| Quick Ratio (X) | 1.04 | 1.74 | 2.30 | 1.84 | 2.03 |
| Inventory Turnover Ratio (X) | 14.08 | 2.81 | 3.28 | 3.19 | 2.61 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 35.67 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 15.65 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 0.00 | 64.33 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 0.00 | 84.35 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 13.34 | 80.42 | 89.47 | 52.56 | 66.35 |
| Interest Coverage Ratio (Post Tax) (X) | 3.05 | 30.86 | 42.80 | 24.38 | 23.91 |
| Enterprise Value (Cr.) | 141.22 | 110.46 | 112.37 | 102.10 | 77.22 |
| EV / Net Operating Revenue (X) | 2.85 | 2.29 | 2.39 | 2.62 | 2.39 |
| EV / EBITDA (X) | 29.83 | 14.10 | 12.87 | 15.17 | 17.93 |
| MarketCap / Net Operating Revenue (X) | 2.93 | 2.44 | 2.57 | 2.85 | 2.69 |
| Retention Ratios (%) | 0.00 | 64.32 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 2.42 | 1.98 | 2.10 | 2.03 | 1.65 |
| Price / Net Operating Revenue (X) | 2.93 | 2.44 | 2.57 | 2.85 | 2.69 |
| EarningsYield | 0.01 | 0.02 | 0.03 | 0.02 | 0.01 |
After reviewing the key financial ratios for Lotus Eye Hospital & Institute Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.36. This value is below the healthy minimum of 5. It has decreased from 1.40 (Mar 24) to 0.36, marking a decrease of 1.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.36. This value is below the healthy minimum of 5. It has decreased from 1.40 (Mar 24) to 0.36, marking a decrease of 1.04.
- For Cash EPS (Rs.), as of Mar 25, the value is 1.80. This value is below the healthy minimum of 3. It has decreased from 3.19 (Mar 24) to 1.80, marking a decrease of 1.39.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 28.85. It has increased from 28.57 (Mar 24) to 28.85, marking an increase of 0.28.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 28.85. It has increased from 28.57 (Mar 24) to 28.85, marking an increase of 0.28.
- For Dividend / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. It has decreased from 0.50 (Mar 24) to 0.00, marking a decrease of 0.50.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 23.83. It has increased from 23.18 (Mar 24) to 23.83, marking an increase of 0.65.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 2.28. This value is within the healthy range. It has decreased from 3.77 (Mar 24) to 2.28, marking a decrease of 1.49.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.83. This value is within the healthy range. It has decreased from 1.97 (Mar 24) to 0.83, marking a decrease of 1.14.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.66. This value is within the healthy range. It has decreased from 1.93 (Mar 24) to 0.66, marking a decrease of 1.27.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.35. This value is below the healthy minimum of 2. It has decreased from 1.40 (Mar 24) to 0.35, marking a decrease of 1.05.
- For PBDIT Margin (%), as of Mar 25, the value is 9.55. This value is below the healthy minimum of 10. It has decreased from 16.24 (Mar 24) to 9.55, marking a decrease of 6.69.
- For PBIT Margin (%), as of Mar 25, the value is 3.48. This value is below the healthy minimum of 10. It has decreased from 8.51 (Mar 24) to 3.48, marking a decrease of 5.03.
- For PBT Margin (%), as of Mar 25, the value is 2.78. This value is below the healthy minimum of 10. It has decreased from 8.32 (Mar 24) to 2.78, marking a decrease of 5.54.
- For Net Profit Margin (%), as of Mar 25, the value is 1.49. This value is below the healthy minimum of 5. It has decreased from 6.04 (Mar 24) to 1.49, marking a decrease of 4.55.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.23. This value is below the healthy minimum of 15. It has decreased from 4.90 (Mar 24) to 1.23, marking a decrease of 3.67.
- For Return on Capital Employeed (%), as of Mar 25, the value is 2.78. This value is below the healthy minimum of 10. It has decreased from 6.79 (Mar 24) to 2.78, marking a decrease of 4.01.
- For Return On Assets (%), as of Mar 25, the value is 1.06. This value is below the healthy minimum of 5. It has decreased from 4.37 (Mar 24) to 1.06, marking a decrease of 3.31.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.72. It has decreased from 0.74 (Mar 24) to 0.72, marking a decrease of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has decreased from 2.25 (Mar 24) to 1.56, marking a decrease of 0.69.
- For Quick Ratio (X), as of Mar 25, the value is 1.04. This value is within the healthy range. It has decreased from 1.74 (Mar 24) to 1.04, marking a decrease of 0.70.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 14.08. This value exceeds the healthy maximum of 8. It has increased from 2.81 (Mar 24) to 14.08, marking an increase of 11.27.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 35.67 (Mar 24) to 0.00, marking a decrease of 35.67.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 15.65 (Mar 24) to 0.00, marking a decrease of 15.65.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 64.33 (Mar 24) to 0.00, marking a decrease of 64.33.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 84.35 (Mar 24) to 0.00, marking a decrease of 84.35.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 13.34. This value is within the healthy range. It has decreased from 80.42 (Mar 24) to 13.34, marking a decrease of 67.08.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.05. This value is within the healthy range. It has decreased from 30.86 (Mar 24) to 3.05, marking a decrease of 27.81.
- For Enterprise Value (Cr.), as of Mar 25, the value is 141.22. It has increased from 110.46 (Mar 24) to 141.22, marking an increase of 30.76.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.85. This value is within the healthy range. It has increased from 2.29 (Mar 24) to 2.85, marking an increase of 0.56.
- For EV / EBITDA (X), as of Mar 25, the value is 29.83. This value exceeds the healthy maximum of 15. It has increased from 14.10 (Mar 24) to 29.83, marking an increase of 15.73.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.93. This value is within the healthy range. It has increased from 2.44 (Mar 24) to 2.93, marking an increase of 0.49.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 64.32 (Mar 24) to 0.00, marking a decrease of 64.32.
- For Price / BV (X), as of Mar 25, the value is 2.42. This value is within the healthy range. It has increased from 1.98 (Mar 24) to 2.42, marking an increase of 0.44.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.93. This value is within the healthy range. It has increased from 2.44 (Mar 24) to 2.93, marking an increase of 0.49.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to 0.01, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lotus Eye Hospital & Institute Ltd:
- Net Profit Margin: 1.49%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 2.78% (Industry Average ROCE: 10.6%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.23% (Industry Average ROE: 10.65%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.05
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.04
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 367 (Industry average Stock P/E: 114.05)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 1.49%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | S.F No.770/12, Avinashi Road, Coimbatore Tamil Nadu 641014 | companysecretary@lotuseye.org http://www.lotuseye.org |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Kavetha Sundaramoorthy | Chairman |
| Ms. Sangeetha Sundaramoorthy | Managing Director |
| Dr. K S Ramalingam | WholeTime Director & CEO |
| Mr. Karthik Veeramani | Director |
| CA. Perumalsamy Mahendran | Director |
| Dr. S Natesan | Director |
FAQ
What is the intrinsic value of Lotus Eye Hospital & Institute Ltd?
Lotus Eye Hospital & Institute Ltd's intrinsic value (as of 11 December 2025) is 106.68 which is 9.59% lower the current market price of 118.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 246 Cr. market cap, FY2025-2026 high/low of 141/55.0, reserves of ₹39.82 Cr, and liabilities of 71.51 Cr.
What is the Market Cap of Lotus Eye Hospital & Institute Ltd?
The Market Cap of Lotus Eye Hospital & Institute Ltd is 246 Cr..
What is the current Stock Price of Lotus Eye Hospital & Institute Ltd as on 11 December 2025?
The current stock price of Lotus Eye Hospital & Institute Ltd as on 11 December 2025 is 118.
What is the High / Low of Lotus Eye Hospital & Institute Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Lotus Eye Hospital & Institute Ltd stocks is 141/55.0.
What is the Stock P/E of Lotus Eye Hospital & Institute Ltd?
The Stock P/E of Lotus Eye Hospital & Institute Ltd is 367.
What is the Book Value of Lotus Eye Hospital & Institute Ltd?
The Book Value of Lotus Eye Hospital & Institute Ltd is 29.2.
What is the Dividend Yield of Lotus Eye Hospital & Institute Ltd?
The Dividend Yield of Lotus Eye Hospital & Institute Ltd is 0.00 %.
What is the ROCE of Lotus Eye Hospital & Institute Ltd?
The ROCE of Lotus Eye Hospital & Institute Ltd is 2.99 %.
What is the ROE of Lotus Eye Hospital & Institute Ltd?
The ROE of Lotus Eye Hospital & Institute Ltd is 1.22 %.
What is the Face Value of Lotus Eye Hospital & Institute Ltd?
The Face Value of Lotus Eye Hospital & Institute Ltd is 10.0.